Updates
What's New in AusDI – March 2025
Browse the latest AusDI drug updates and medicines information – created and curated by trusted Australian editorial pharmacists, monthly.
Drug Monographs
Content Updates to Monographs
As part of our rigorous editorial updating process, the AusDI editorial team monitors safety information issued by the Australian Therapeutic Goods Administration (TGA), the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), the New Zealand Medicines and Medical Devices Safety Authority (Medsafe), and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). FDA-approved indications and dosing information in adults and children are also reviewed by our editorial team and included in selected monographs.
The Bupropion (Systemic) monograph has been updated with information on Brugada syndrome based on changes to product information. The use of bupropion may unmask Brugada syndrome, a rare genetic disease of the cardiac sodium channel characterised by electrocardiogram (ECG) changes, which may result in cardiac arrest and/or sudden death. Caution is recommended in patients with Brugada syndrome or risk factors such as a family history of cardiac arrest or sudden death.
Past Content Updates
February 2025
The Bupropion (Systemic) monograph has been updated with information on Brugada syndrome based on changes to product information. The use of bupropion may unmask Brugada syndrome, a rare genetic disease of the cardiac sodium channel characterised by electrocardiogram (ECG) changes, which may result in cardiac arrest and/or sudden death. Caution is recommended in patients with Brugada syndrome or risk factors such as a family history of cardiac arrest or sudden death.
January 2025
The Levetiracetam (Systemic) monograph has been updated with information on drug reaction with eosinophilia and systemic symptoms (DRESS) based on changes to product information. Rare cases of DRESS, also known as multiorgan hypersensitivity reactions, have been reported in patients taking levetiracetam. It is recommended that levetiracetam be discontinued if DRESS is suspected.
December 2024
The Gabapentin (Systemic) monograph has been updated with information on pregnancy based on changes to product information. The Australian pregnancy category for gabapentin has been updated to category D (previously category B3). The use of gabapentin during the first trimester of pregnancy may cause major birth defects. It is recommended that gabapentin not be used during pregnancy unless the anticipated benefits clearly outweigh the potential risks. It is recommended that women of child-bearing potential use effective contraception during gabapentin treatment.
November 2024
The Abatacept (Systemic) monograph has been updated to include information on progressive multifocal leucoencephalopathy (PML) based on changes to product information. There have been cases of PML reported in patients receiving abatacept, mostly during concurrent use with other immunosuppressive medicines. It is recommended that PML be considered in the differential diagnosis in immunosuppressed patients who develop new or worsening cognitive, neurological, and psychiatric symptoms. It is recommended that abatacept be discontinued and appropriate diagnostic measures initiated if symptoms suggestive of PML occur.
New Product Summary
Apohealth Children's Antihistamine
Apohealth Dexchlorpheniramine Allergy Relief
Blooms the Chemist Promethazine Allergy Relief
Chemists' Own Paracetamol Pain Relief
Ezetimibe - Rosuvastatin Sandoz
Water for Injections [InterPharma]
New Product Information
Apohealth Children's Antihistamine
Product information with an update to safety includes Afluria Quad, Apo-Baclofen, Apo-Ciprofloxacin, Apo-Donepezil, Apo-Norfloxacin, Apo-Olmesartan/Amlodipine, Apo-Olmesartan/Amlodipine/HCTZ, Aspalgin, Avloire, Bavencio, Cabenuva, Carbamazepine Sandoz, Cholstat, Ciprol, DBL Fentanyl, Diprivan, Dolapril, Dolased Forte, Dovato, Edurant, Entyvio, Eutroxsig, Ezetimibe Sandoz, Fluad Quad, Flucelvax Quad, Fluconazole-Baxter, Fresofol MCT/LCT, Idefirix, Imbruvica, Imuran, Inlyta, Juluca, Kalixocin, Klacid, Kymriah, Levetiracetam-GH Tablets, Lukair, Neotigason, Nexium, Nexium Hp7, Nexium IV, Olmekar, Oroxine, Panadol Rapid Caplets, Panadol Tablets and Panadol Mini Caps, Picosalax, Pravastatin Sandoz, Premarin, Provera, Rabeprazole Sandoz, Ralovera, Retevmo, Roaccutane, Rotarix Oral Liquid, Saxenda, Singulair, Solu-Cortef, Spikevax XBB.1.5, Stelax, Tadalafil Sandoz, Taltz, Tanilone, Tegretol, Tenofovir GH, Tivicay and Tivicay PD, Tobramycin Viatris, Triumeq, Valcyte, Vaxigrip Tetra, Velsipity, Victoza, Voltaren Rapid Extra Strength, and Zavicefta.
Product information with an update to indications includes Blincyto, Imfinzi, and Pramin.
New Consumer Medicine Information
Apohealth Children's Antihistamine
Blooms The Chemist Prochlorperazine
Blooms The Chemist Promethazine
Try AusDI for FREE
To try one of Australia’s most efficient and comprehensive drug information databases, register for a 14-day FREE trial by filling in the form below.
We’ll be in touch with more information to help you get started soon.